StreetAlpha.app
Home › Stocks › NAMS

NewAmsterdam Pharma Co N.V. (NAMS)

Healthcare
$19.39
▼ −0.36%
LAST CLOSE · NOV 17

NewAmsterdam Pharma develops obicetrapib, an oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol. It last closed at $19.39 on Nov 17, down 0.36% on the day. The average 12-month price target from 4 analysts is $50.25 (+159.2% from the last close), with a high of $61.00 and a low of $42.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in NAMS, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $1.6M, the largest $659K.

AI Auto Pilots
Is NAMS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$25.9M
−26.4% vs a year ago
Net income
−$204.9M
−789.9% margin
EPS (diluted)
−$1.69
Free cash flow
−$150.9M
−581.6% margin
Valuation
Market cap
$2.3B
119.9M shares
P/E
–
No P/E while losing money
Price to sales
89.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$423.1M
At Sep 30
Shareholder equity
$630.8M
Shares outstanding
119.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $102.7M$102.7MFY2022FY2023: $14.1M$14.1MFY2023FY2024: $45.6M$45.6MFY2024FY2025: $22.5M$22.5MFY2025

From NAMS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on NAMS in the past 90 days
Average 12-month target
$50.25
▲ 159.2% upside

Based on 4 analysts who set a price target on NAMS in the past 90 days. The average target is $50.25, with a high of $61.00 and a low of $42.00, compared with the last close of $19.39.

Low $42.00Avg $50.25High $61.00
Blue marker: last close $19.39
Highest target$61.00
Average target$50.25
Lowest target$42.00
Latest rating changes
Cantor FitzgeraldMaintained
Nov 11Buy$61
NeedhamMaintained
Nov 5Buy$46
RBC CapitalTarget lowered
Oct 5Buy$50 → $42
HC Wainwright & Co.Reiterated
Sep 8Buy$52
RBC CapitalTarget lowered
Aug 6Buy$51 → $50
DateFirmActionRatingPrice target
Nov 11Cantor FitzgeraldMaintainedBuy$61
Nov 5NeedhamMaintainedBuy$46
Oct 5RBC CapitalTarget loweredBuy$50 → $42
Sep 8HC Wainwright & Co.ReiteratedBuy$52
Aug 6RBC CapitalTarget loweredBuy$51 → $50
Loading…

Technical Analysis

NAMS · as of the Nov 17 close · updated after every close
Downtrend

The stock is 3% below its 20 day and 10% below its 50 day average. It is 50% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 43). The nearest support is the swing low (Oct 23) at $19.13, and the nearest resistance the Pivot at $19.53.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 6.8%/day
Key levels
$42.2152 week high+117.7%
$29.04200 day average+49.8%
$25.39100 day average+30.9%
$21.2850 day average+9.7%
$20.82Swing high (Nov 11)+7.4%
$20.16Pivot R1+4.0%
$20.0420 day average+3.4%
$19.53Pivot+0.7%
$19.39Last close
$19.13Swing low (Oct 23)−1.3%
$18.76Pivot S1−3.2%
$17.9052 week low−7.7%
Indicators
RSI (14)43.26Middle of its rangeNeutral
MACD-0.57Above its signal lineBullish
Stochastic40.4Middle of its rangeNeutral
ADX (14)15.0No clear trend
Williams %R-65.8Oversold below −80, overbought above −20Neutral
CCI (20)-67.4Oversold below −100, overbought above 100Neutral
Rate of change−2.6%Change over 10 sessionsBearish
ATR (14)$1.32Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NAMS

What happened before

See how NAMS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish0 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow NAMS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NAMS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
0
0%
Bearish
3
100%
Date span
Sep 8 – Oct 21
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$1.6M
Largest print
$659K
Loading…

NAMS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 83 selling
  • ▲Held by funds +5.7 pts
  • ▼Funds holding -12
  • ▼Superinvestors: 2 added, 3 cut
  • ▲Put/call 14.81 to 1.79
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding183195−6.2%
In funds' top 1056−16.7%
Held by funds107.4%101.7%+5.7 pts
New / increased24 / 8345 / 70−7.0%
Reduced / sold out47 / 3650 / 20+18.6%
Put/call ratio1.7914.81−87.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NAMS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAMS is in one of them and how their past NAMS trades turned out.

NAMS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NAMS in an article yet. Here's the latest on the wider market.

About NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma is a biopharmaceutical company based in Naarden, Netherlands. It is developing obicetrapib, a once-a-day oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol who do not reach their targets on statins alone. The drug can be taken on its own or combined with ezetimibe, another cholesterol-lowering pill. The company plans to sell it in the United States itself and has given Menarini the rights to market it in most of Europe.

Headquarters
Narrden, Netherlands